A clinical perspective of obesity, metabolic syndrome and cardiovascular disease

Thang S Han, Mike Ej Lean, Thang S Han, Mike Ej Lean

Abstract

The metabolic syndrome is a condition characterized by a special constellation of reversible major risk factors for cardiovascular disease and type 2 diabetes. The main, diagnostic, components are reduced HDL-cholesterol, raised triglycerides, blood pressure and fasting plasma glucose, all of which are related to weight gain, specifically intra-abdominal/ectopic fat accumulation and a large waist circumference. Using internationally adopted arbitrary cut-off values for waist circumference, having metabolic syndrome doubles the risk of cardiovascular disease, but offers an effective treatment approach through weight management. Metabolic syndrome now affects 30-40% of people by age 65, driven mainly by adult weight gain, and by a genetic or epigenetic predisposition to intra-abdominal/ectopic fat accumulation related to poor intra-uterine growth. Metabolic syndrome is also promoted by a lack of subcutaneous adipose tissue, low skeletal muscle mass and anti-retroviral drugs. Reducing weight by 5-10%, by diet and exercise, with or without, anti-obesity drugs, substantially lowers all metabolic syndrome components, and risk of type 2 diabetes and cardiovascular disease. Other cardiovascular disease risk factors such as smoking should be corrected as a priority. Anti-diabetic agents which improve insulin resistance and reduce blood pressure, lipids and weight should be preferred for diabetic patients with metabolic syndrome. Bariatric surgery offers an alternative treatment for those with BMI ≥ 40 or 35-40 kg/m(2) with other significant co-morbidity. The prevalence of the metabolic syndrome and cardiovascular disease is expected to rise along with the global obesity epidemic: greater emphasis should be given to effective early weight-management to reduce risk in pre-symptomatic individuals with large waists.

Keywords: Coronary heart disease; bariatric surgery; diabetes; insulin resistance; weight management.

References

    1. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007; 17: 319–326.
    1. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
    1. Cannon RO, Epstein SE. Microvascular angina as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988; 62: 1338–1343.
    1. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158–161.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143–3421.
    1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.
    1. Feldman RD, Anderson TJ, Touyz RM. Metabolic syndrome sinkholes: what to do when Occam’s razor gets blunted. Can J Cardiol 2015; 31: 601–604.
    1. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812–819.
    1. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–673.
    1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
    1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
    1. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250.
    1. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization, 1995.
    1. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991; 65: 105–114.
    1. Lean ME, Han TS, Deurenberg P. Predicting body composition by densitometry from simple anthropometric measurements. Am J Clin Nutr 1996; 63: 4–14.
    1. Seidell JC, Han TS, Feskens EJ, et al. Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med 1997; 242: 401–406.
    1. Al-Gindan YY, Hankey CR, Govan L, et al. Derivation and validation of simple anthropometric equations to predict adipose tissue mass and total fat mass with MRI as the reference method. Br J Nutr 2015; 114: 1852–1867.
    1. Al-Gindan YY, Hankey C, Govan L, et al. Derivation and validation of simple equations to predict total muscle mass from simple anthropometric and demographic data. Am J Clin Nutr 2014; 100: 1041–1051.
    1. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.
    1. Swinburn B, Egger G, Raza F. Dissecting obesogenic environments. The development and application of a framework for identifying and prioritizing environmental interventions for obesity. Prev Med 1999; 29: 563–570.
    1. French SA, Story M, Jeffery RW. Environmental influences on eating and physical activity. Annu Rev Public Health 2001; 22: 309–335.
    1. Vanhala M, Vanhala P, Kumpusalo E, et al. Relation between obesity from childhood to adulthood and the metabolic syndrome: population based study. BMJ 1998; 317: 319–319.
    1. Smoyer-Tomic KE, Spence JC, Raine KD, et al. The association between neighborhood socioeconomic status and exposure to supermarkets and fast food outlets. Health Place 2008; 14: 740–754.
    1. Laakso M. Gene variants, insulin resistance, and dyslipidaemia. Curr Opin Lipidol 2004; 15: 115–120.
    1. Bouchard C. Genetics and the metabolic syndrome. Int J Obes 1995; 19(suppl 1): S52–S59.
    1. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889–894.
    1. Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 2007; 3: e115–e115.
    1. Loos RJ, Yeo GS. The bigger picture of FTO: the first GWAS-identified obesity gene. Nat Rev Endocrinol 2014; 10: 51–61.
    1. Hofker M, Wijmenga C. A supersized list of obesity genes. Nat Genet 2009; 41: 139–140.
    1. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903–908.
    1. Han TS, McNeill G, Campbell DM. The relationship between women’s birth weight and their current intra-abdominal fat-mass. Proc Nutr Soc 1995; 54: 182A–182A.
    1. Gascoin-Lachambre G, Buffat C, Rebourcet R, et al. Cullins in human intra-uterine growth restriction: expressional and epigenetic alterations. Placenta 2010; 31: 151–157.
    1. Han TS, Hart CL, Haig C, et al. Contributions of maternal and paternal adiposity and smoking to adult offspring adiposity and cardiovascular risk: the Midspan Family Study. BMJ Open 2015; 5: e007682–e007682.
    1. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 2001; 24: 683–689.
    1. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643–1649.
    1. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514–1520.
    1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318–368.
    1. Swislocki AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419–423.
    1. Pontiroli AE, Alberetto M, Pozza G. Patients with insulinoma show insulin resistance in the absence of arterial hypertension. Diabetologia 1992; 35: 294–295.
    1. Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477–484.
    1. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583–2589.
    1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875–880.
    1. Han TS, Williams K, Sattar N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10: 923–931.
    1. Björntorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493–496.
    1. Lean ME, James WP, Jennings G, et al. Brown adipose tissue uncoupling protein content in human infants, children and adults. Clin Sci (Lond) 1986; 71: 291–297.
    1. Semple RK, Chatterjee VK, O’Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 581–589.
    1. Guettier JM, Park JY, Cochran EK, et al. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin Endocrinol (Oxf) 2008; 68: 547–554.
    1. Walker UA, Kirschfink M, Peter HH. Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation. Rheumatology 2003; 42: 393–394.
    1. Bauman WA, Spungen AM. Metabolic changes in persons after spinal cord injury. Phys Med Rehabil Clin N Am 2000; 11: 109–140.
    1. Han TS, Walker BR, Arlt W, et al. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol 2014; 10: 115–124.
    1. Han TS, Stimson RH, Rees DA, et al. United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2013; 78: 197–203.
    1. Greenfield DM, Blewitt A, Coleman RE, et al. Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clin Endocrinol (Oxf) 2015. Epub ahead of print 6 August 2015. DOI: 10.1111/cen.12869.
    1. Barker DJP. Fetal and infant origins of adult disease. BMJ 1990; 301: 1111–1111.
    1. Lean ME, Han TS, Bush H, et al. Ethnic differences in anthropometric and lifestyle measures related to coronary heart disease risk between South Asian, Italian and general-population British women living in the west of Scotland. Int J Obes Relat Metab Disord 2001; 25: 1800–1805.
    1. Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283: 2253–2259.
    1. Bhopal R. What is the risk of coronary heart disease in South Asians? A review of UK research. J Public Health Med 2000; 22: 375–385.
    1. Nightingale CM, Rudnicka AR, Owen CG, et al. Influence of adiposity on insulin resistance and glycemia markers among U.K. Children of South Asian, black African-Caribbean, and white European origin: child heart and health study in England. Diabetes Care 2013; 36: 1712–1719.
    1. Tanner CJ, Barakat HA, Dohm GL, et al. Muscle fiber type is associated with obesity and weight loss. Am J Physiol Endocrinol Metab 2002; 282: E1191–E1196.
    1. Hall LM, Moran CN, Milne GR, et al. Fat oxidation, fitness and skeletal muscle expression of oxidative/lipid metabolism genes in South Asians: implications for insulin resistance? PLoS One 2010; 5: e14197–e14197.
    1. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord 2014; 14: 9–9.
    1. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216–219.
    1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.
    1. Lahti-Koski M. Body mass index and obesity among adults in Finland. Doctoral dissertation, Department of Public Health, University of Helsinki Helsinki, Finland, 2001.
    1. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives. Washington, DC: US Department of Health and Human Services, Public Health Service, 1990; DHHS publication no. (PHS)90-50212.
    1. Department of Health. Alcohol Guidelines Review – Report from the Guidelines development group to the UK Chief Medical Officers, January 2016. Produced by William Lea for the Department of Health.
    1. Lawlor DA, Lean ME, Sattar NA. Obesity and a wider impact on vascular disease. BMJ 2006; 18: 1060–1063.
    1. Williams B, Poulter NR, Brown MJ, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634–640.
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
    1. Naude CE, Schoonees A, Senekal M, et al. Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis. PLoS One 2014; 9: e100652–e100652.
    1. Boaz M, Raz O, Wainstein J. Low fat vs. low carbohydrate diet strategies for weight reduction: a meta-analysis. J Obes Weight Loss Ther 2015; 5: 2–2.
    1. Laaksonen DE, Lakka HM, Salonen JT, et al. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 2002; 25: 1612–1618.
    1. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–242.
    1. Fujioka K, Seaton TB, Rowe E, et al. Sibutramine/Diabetes Clinical Study Group Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175–187.
    1. Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. TheORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004; 20: 1393–1401.
    1. Torp-Pedersen C, Caterson I, Coutinho W, et al. Investigators SCOUT. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915–2923.
    1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–1705.
    1. Astrup A, Rössner S, Van Gaal L, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606–1616.
    1. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049–2057.
    1. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94: 846–852.
    1. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159–166.
    1. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34–56.
    1. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595–605.
    1. National Institute for Health and Clinical Excellence (NICE). Clinical guideline 43. Obesity guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. (2006).
    1. NHS Health and Social Care Information Centre. Statistics on obesity, physical activity and diet: England. (2012).
    1. Health and Human Service’s Agency for Healthcare Research and Quality. Obesity surgeries have jumped dramatically since 1998. .
    1. Kuesters S, Grueneberger JM, Baumann T, et al. Revisionary bariatric surgery: indications and outcome of 100 consecutive operations at a single center. Surg Endoscy 2012; 26: 1718–1723.
    1. Sosa JL, Pombo H, Pallavicini H, et al. Laparoscopic gastric bypass beyond age 60. Obes Surg 2004; 14: 1398–1401.
    1. Lean M, Brosnahan N, McLoone P, et al. Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract 2013; 63: 115–124.
    1. Rector RS, Warner SO, Liu Y, et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 2007; 293: E500–E506.
    1. Muzio F, Mondazzi L, Sommariva D, et al. Long-term effects of low-calorie diet on the metabolic syndrome in obese nondiabetic patients. Diabetes Care 2005; 28: 1485–1486.
    1. Case CC, Jones PH, Nelson K, et al. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002; 4: 407–414.
    1. Christensen P, Bliddal H, Riecke BF, et al. Comparison of a low-energy diet and a very low-energy diet in sedentary obese individuals: a pragmatic randomized controlled trial. Clin Obes 2011; 1: 31–40.
    1. Wing RR, Bolin P, Brancati FL, et al. Look AHEAD and Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145–154.
    1. Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc 2008; 83: 897–907.
    1. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610–617.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera